Clinical Trials Logo

Giant Cell Glioblastoma clinical trials

View clinical trials related to Giant Cell Glioblastoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04489420 Terminated - Clinical trials for Glioblastoma Multiforme

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

CYNK001GBM01
Start date: October 1, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.

NCT ID: NCT01836549 Terminated - Glioblastoma Clinical Trials

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Start date: March 2013
Phase: Phase 2
Study type: Interventional

This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01095094 Terminated - Glioblastoma Clinical Trials

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Start date: January 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ritonavir together with lopinavir works in treating patients with progressive or recurrent high-grade glioma.